OneDigital Investment Advisors LLC Raises Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

OneDigital Investment Advisors LLC increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 62.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,817 shares of the pharmaceutical company's stock after purchasing an additional 1,086 shares during the quarter. OneDigital Investment Advisors LLC's holdings in Vertex Pharmaceuticals were worth $1,310,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of VRTX. Capital World Investors lifted its holdings in Vertex Pharmaceuticals by 17.2% in the first quarter. Capital World Investors now owns 25,567,184 shares of the pharmaceutical company's stock valued at $10,687,339,000 after acquiring an additional 3,761,414 shares during the period. Capital Research Global Investors lifted its stake in shares of Vertex Pharmaceuticals by 61.0% in the 1st quarter. Capital Research Global Investors now owns 5,743,882 shares of the pharmaceutical company's stock valued at $2,401,000,000 after purchasing an additional 2,176,218 shares during the period. Swedbank AB purchased a new stake in Vertex Pharmaceuticals during the first quarter worth $277,317,000. AMF Tjanstepension AB acquired a new stake in Vertex Pharmaceuticals during the second quarter valued at $257,655,000. Finally, International Assets Investment Management LLC increased its holdings in Vertex Pharmaceuticals by 74,015.5% in the third quarter. International Assets Investment Management LLC now owns 324,626 shares of the pharmaceutical company's stock valued at $150,977,000 after buying an additional 324,188 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company's stock.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 3,784 shares of the firm's stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $499.00, for a total value of $1,888,216.00. Following the completion of the transaction, the chairman now owns 9,994 shares of the company's stock, valued at $4,987,006. This trade represents a 27.46 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Sangeeta N. Bhatia sold 646 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $500.00, for a total value of $323,000.00. Following the completion of the transaction, the director now owns 4,435 shares of the company's stock, valued at $2,217,500. The trade was a 12.71 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,445 shares of company stock worth $2,218,394. 0.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on VRTX shares. Citigroup started coverage on Vertex Pharmaceuticals in a research report on Thursday, November 14th. They set a "buy" rating and a $575.00 target price on the stock. Needham & Company LLC restated a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Friday, July 26th. TD Cowen increased their target price on Vertex Pharmaceuticals from $450.00 to $500.00 and gave the company a "buy" rating in a research report on Tuesday, July 23rd. Bank of America reduced their price objective on shares of Vertex Pharmaceuticals from $550.00 to $541.00 and set a "buy" rating for the company in a research report on Monday, October 14th. Finally, Royal Bank of Canada increased their price objective on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a "sector perform" rating in a report on Tuesday, November 5th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $499.12.

Vertex Pharmaceuticals Trading Down 4.1 %

Shares of NASDAQ:VRTX traded down $19.00 during midday trading on Tuesday, reaching $448.01. 2,191,299 shares of the company's stock were exchanged, compared to its average volume of 1,183,779. The stock has a market cap of $115.38 billion, a price-to-earnings ratio of -226.57 and a beta of 0.39. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $346.29 and a fifty-two week high of $519.88. The firm's 50 day simple moving average is $476.31 and its two-hundred day simple moving average is $472.56. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. During the same period in the prior year, the business posted $3.67 EPS. The business's revenue for the quarter was up 11.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.82 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.